Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
Eli Lilly has shared positive results from a Phase II clinical trial (NCT06230523) evaluating eloralintide, an investigational once-weekly, selective amylin receptor, in adults with obesity or ...
BioInvent International AB ( ($SE:BINV) ) has issued an announcement. BioInvent International AB announced promising Phase 1 clinical data for its ...
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the Phase III HARMONi trial featuring the novel, potential first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback